Insulet had four patents in mobile during Q1 2024. Insulet Corp’s patents filed in Q1 2024 focus on safety and accuracy measures in medicament delivery devices. These devices can identify duplicate boluses, set limits on doses, automatically detect meals, deliver partial boluses based on glucose levels, and resolve conflicts among multiple devices. Additionally, the patents describe determining anticipated basal insulin delivery actions based on glucose levels and providing recommendations to prevent undesired high or low glucose levels in the future. GlobalData’s report on Insulet gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Insulet Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Insulet grant share with mobile as a theme is 50% in Q1 2024. Grant share is based on the ratio of number of grants to total number of patents.

Recent Patents

Application: Safety and accuracy measures for medicament bolus delivery (Patent ID: US20240075214A1)

The patent filed by Insulet Corp. describes a medicament delivery device that incorporates safety and accuracy measures to prevent the inadvertent delivery of duplicate medicament boluses. The device sets limits for maximum allowable medicament bolus doses and maximum cumulative bolus doses over an interval. It also features automatic meal detection to adjust or reject user-requested medicament bolus doses based on glucose level trends. Additionally, the device allows for the delivery of partial boluses and the delivery of remainders of boluses based on acceptable glucose level trends. The patent also addresses potential conflicts among multiple medicament delivery devices by providing a single actor, such as a medicament delivery controller, with sole control over dosing and delivery.

The claims of the patent detail methods performed by a processor of an insulin delivery device, including monitoring glucose levels, adjusting insulin bolus doses based on glucose level trends, and delivering adjusted bolus doses to the user. The device can determine if the user has eaten within an interval or already received a bolus of insulin, adjusting the specified bolus dose accordingly. The patent also covers the use of external electronic devices for insulin delivery management, analyzing glucose level trends to identify meal ingestion, and adjusting insulin doses based on various scenarios. Furthermore, the patent describes an insulin delivery system with a single entity in control of determining doses and causing insulin delivery, featuring a bolus calculator, controller, processor, and user interface for automated insulin delivery to the user.

To know more about GlobalData’s detailed insights on Insulet, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.